<DOC>
	<DOCNO>NCT02569502</DOCNO>
	<brief_summary>This study evaluate safety tolerability subcutaneous Fuzeon patient advance HIV-1 infection unable construct appropriate treatment regimen currently available antiretroviral agent . The anticipated time study treatment 3-12 month , target sample size 9 individual .</brief_summary>
	<brief_title>A Study Enfuvirtide ( Fuzeon ) Patients With Advanced Human Immunodeficiency Virus-1 ( HIV-1 ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>Adult adolescent patient great ( &gt; ) 16 year age HIV1 infection CD4 count le ( &lt; ) 350/cubic millimeter ( mm^3 ) HIV RNA viral load &gt; 10,000 copy per milliliter ( copies/mL ) highly active antiretroviral therapy ( HAART ) Documented resistance , treatmentlimiting toxicity , and/or &gt; =6 month ' prior experience 3 currently available class antiretroviral drug . Women pregnant breastfeeding ; Patients unable selfinject ; Active , untreated opportunistic infection .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>